scispace - formally typeset
A

Andreas J. Gross

Researcher at University of Göttingen

Publications -  154
Citations -  3542

Andreas J. Gross is an academic researcher from University of Göttingen. The author has contributed to research in topics: Medicine & Laser. The author has an hindex of 28, co-authored 129 publications receiving 3122 citations.

Papers
More filters
Journal ArticleDOI

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids.

TL;DR: The data indicate that hybrid cell vaccination is a safe and effective therapy for renal cell carcinoma and may provide a broadly applicable strategy for other malignancies with unknown antigens.
Journal ArticleDOI

Supine Versus Prone Position During Percutaneous Nephrolithotomy: A Report from the Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study

TL;DR: The choice of patient position should be tailored to individual patient characteristics and the surgeon's preference, since operative time and stone-free rates favor prone PCNL, but patient safety favors supine PCNL.
Journal ArticleDOI

Feasibility and efficacy of Thulium:YAG laser enucleation (VapoEnucleation) of the prostate

TL;DR: The functional outcomes demonstrate efficiency of Tm:YAG VapoEnucleation for patients with larger prostates and learning curve in Vapoenucleation is short and complications are minimal, and no limitation in prostate size occurs.
Journal ArticleDOI

RevoLix™ vaporesection of the prostate: initial results of 54 patients with a 1-year follow-up

TL;DR: Preliminary results indicate that RevoLix™ vaporesection of the prostate is safe and efficient and a significant improvement in voiding symptoms and patients’ quality of life is shown.
Journal ArticleDOI

Anticoagulation and Antiplatelet Therapy in Urological Practice: ICUD/AUA Review Paper

TL;DR: Multidisciplinary management of anticoagulant/antiplatelet medications for patients with recent thromboembolic events, mechanical cardiac valves, atrial fibrillation and cardiac stents would reduce the high morbidity and mortality of inexpertly discontinuing or modifying these lifesaving therapies.